Marshall Wace’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Marshall Wace’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-74,500	Closed	-$1.8M	–	3208
2023 Q1	$1.8M	Buy	+74,500	New	+$935K	﹤0.01%	1510
2022 Q4	–	Sell	-80,685	Closed	-$362K	–	3649
2022 Q3	$362K	Buy	80,685 +63,577	+372%	+$290K	﹤0.01%	2873
2022 Q2	$69K	Buy	+17,108	New	+$81.1K	﹤0.01%	3309
2021 Q2	–	Sell	-24,416	Closed	-$256K	–	3281
2021 Q1	$256K	Buy	+24,416	New	+$344K	﹤0.01%	2176
2020 Q4	–	Sell	-46,545	Closed	-$598K	–	2282
2020 Q3	$598K	Sell	46,545 -192,928	-81%	-$2.44M	﹤0.01%	1184
2020 Q2	$3.38M	Buy	+239,473	New	+$3.02M	0.02%	602

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Marshall Wace's PRVB Position: Q2 2023 in Review

Marshall Wace sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 74,500 shares — an estimated $1.8M sold.

Marshall Wace first reported a position in PRVB in Q2 2020 and held it in 6 quarters. The position peaked at $3.38M in Q2 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Marshall Wace reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Marshall Wace sold 74,500 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $1.8M.
Marshall Wace first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
Marshall Wace's Provention Bio, Inc. Common Stock position peaked at $3.38M in Q2 2020.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.